Results 61 to 70 of about 1,690 (152)

Hypolypidemic therapy in the XXI century: what is new?

RUDN Journal of Medicine
Relevance. The leading position in mortality throughout the world is occupied by cardiovascular diseases, caused be atherosclerosis process. Statins used to be the gold standard of lipid-lowering therapy for a long time due to their high efficacy ...
Natalya Yu. Ob’edkova, Diana N. Usacheva, Galina S. Mal, Evgenij G. Ob’edkov   +3 more
doaj   +1 more source

Disentangling Organ‐Specific Roles of Farnesoid X Receptor in Bile Acid and Glucolipid Metabolism

Liver International, Volume 45, Issue 4, April 2025.
ABSTRACT Background and Aims The farnesoid X receptor (FXR) is an attractive pharmaceutical target for metabolic dysfunction‐associated steatotic liver disease (MASLD). However, its tissue‐specific roles in energy metabolism remain controversial, hindering the development of effective therapies. To address this, new approaches are required.
Tingting Li, Chenyang Fu, Zhongzheng Tang, Changkun Li, Duanyi Hua, Bei Liu, Zheying Tao, Jie Yang, Li Zhang, Tingting Cheng, Shujie Wang, Guang Ning, Yanyun Gu   +12 more
wiley   +1 more source

Modeling hypercholesterolemia and vascular lipid accumulation in LDL receptor mutant zebrafish

Journal of Lipid Research, 2018
Elevated plasma LDL cholesterol is the dominant risk factor for the development of atherosclerosis and cardiovascular disease. Deficiency in the LDL receptor (LDLR) is a major cause of familial hypercholesterolemia in humans, and the LDLR knockout mouse ...
Chao Liu, Young Sook Kim, Jungsu Kim, Jennifer Pattison, Andrés Kamaid, Yury I. Miller   +5 more
doaj   +1 more source

Intensive Combination LDL-Lowering Therapy in a Patient With Homozygous Familial Hypercholesterolemia

JACC: Case Reports
We present a young boy with a diagnosis of homozygous familial hypercholesterolemia who presented with statin and ezetimibe resistance. The patient received lipoprotein apheresis at 6 years of age.
Hayato Tada, MD, Hirofumi Okada, MD, Masa-aki Kawashiri, MD, Masayuki Takamura, MD   +3 more
doaj   +1 more source

Inhibition of hepatic microsomal triglyceride transfer protein – a novel therapeutic option for treatment of homozygous familial hypercholesterolemia

Vascular Health and Risk Management, 2014
Alpo Vuorio,1,2 Matti J Tikkanen,3 Petri T Kovanen4 1Health Center Mehiläinen, Vantaa, Finland; 2Finnish Institute of Occupational Health, Lappeenranta, Finland; 3Heart and Lung Center, Helsinki University Central Hospital, Folkhälsan Research ...
Vuorio A, Tikkanen MJ, Kovanen PT
doaj  

Comparison of γ-Oryzanol Content Using HPLC Profiling and Bioactivity in Three Indonesian Brown Rice (Oryza sativa L.) Varieties

Indonesian Journal of Chemistry
Brown rice (BrR) is a nutrient-rich staple food and a potential source of γ-oryzanol, which has the potential to promote health effects in hypercholesterolemia.
Ja’far Umar, Christine Natalia Palis, Eko Suyanto, Turhadi Turhadi, Titin Andri Wihastuti, Fatchiyah Fatchiyah   +5 more
doaj   +1 more source

Real-world safety and efficacy of lomitapide in homozygous familial hypercholesterolemia: interim report of special-use survey in Japan.

Future Cardiology
Aim: To evaluate the safety and efficacy of lomitapide in real-world clinical practice in Japan. Patients & methods: Interim analysis of 39 patients with homozygous familial hypercholesterolemia from an all-case surveillance study.
M. Harada‐Shiba, Shigenori Haruna, Noriaki Kogawa   +2 more
semanticscholar   +1 more source

Breaking barriers: Innovative therapies for managing homozygous familial hypercholesterolemia

Experimental and Molecular Pathology
Homozygous familial hypercholesterolemia (HoFH) is a rare autosomal recessive disorder characterized by variants in genes involved in the regulation of low-density lipoprotein cholesterol (LDL-C) metabolism.
Shuai-Jie Huang, Ping Huang, Nan-Nan Song, Xian-Hui Jia, Hong-Li Gao, Zhi-Yuan Lu, Xiao-Lan Wen   +6 more
doaj   +1 more source

Machine learning, molecular docking and simulation studies reveal Lomitapide, Lodipamide, Zafirlukast, Netupitant and Salmon Calcitonin as potent drug molecules against Chagas disease

bioRxiv
Trypanosoma cruzi (T. cruzi), a protozoan parasite, is the pathogen that causes the hazardous disease Chagas, sometimes referred to as American trypanosomiasis. Currently, there are just two drugs commercially available to treat this fatal condition. So,
Kavya Singh, Navjeet Kaur, Ashish Prabhu
semanticscholar   +1 more source

Unlocking the mysteries of VLDL: exploring its production, intracellular trafficking, and metabolism as therapeutic targets

Lipids in Health and Disease
Reducing circulating lipid levels is the centerpiece of strategies for preventing and treating atherosclerotic cardiovascular disease (ASCVD). Despite many available lipid-lowering medications, a substantial residual cardiovascular risk remains.
Jingfei Chen, Zhenfei Fang, Qin Luo, Xiao Wang, Mohamad Warda, Avash Das, Federico Oldoni, Fei Luo   +7 more
doaj   +1 more source